Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
@article{Hosie2006EndogenousNR, title={Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites}, author={Alastair M. Hosie and Megan E. Wilkins and Helena da Silva and Trevor G. Smart}, journal={Nature}, year={2006}, volume={444}, pages={486-489} }
Inhibitory neurotransmission mediated by GABAA receptors can be modulated by the endogenous neurosteroids, allopregnanolone and tetrahydro-deoxycorticosterone. Neurosteroids are synthesized de novo in the brain during stress, pregnancyand after ethanol consumption, and disrupted steroid regulation of GABAergic transmission is strongly implicated in several debilitating conditions such as panic disorder, major depression, schizophrenia, alcohol dependence and catamenial epilepsy. Determining how…
668 Citations
Physiological roles of endogenous neurosteroids at α2 subunit-containing GABAA receptors
- Biology, Psychology
- 2012
The α2Q241M knock-ins showed greater anxiety levels in two classical rodent anxiety paradigms, consistent with endogenous neurosteroids mediating anxiolysis via α2-type GABAA receptors, which would identify the α2 isoform as an appropriate target for generating receptor subtype-selective neurosteroid therapeutics for anxiety disorders.
Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABAA receptors
- BiologyProceedings of the National Academy of Sciences
- 2014
The ability of neurosteroids to modulate the phosphorylation and membrane insertion of α4 subunit-containing GABAARs may underlie the profound effects these endogenous signaling molecules have on neuronal excitability and behavior.
Brain neurosteroids are natural anxiolytics targeting α2 subunit γ-aminobutyric acid type-A receptors
- Biology, Psychology
- 2018
It is revealed that α2-GABAAR targeting neurosteroids may act as selective anxiolytics for the treatment of anxiety disorders, providing new therapeutic opportunities for drug development.
Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors.
- Biology, MedicinePharmacology & therapeutics
- 2007
Multiple roles for the first transmembrane domain of GABAA receptor subunits in neurosteroid modulation and spontaneous channel activity
- BiologyNeuroscience Letters
- 2010
Neurosteroid interactions with synaptic and extrasynaptic GABAA receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability
- BiologyPsychopharmacology
- 2013
This review provides a critical appraisal of recent advances in the pharmacology of endogenous neurosteroids that interact with GABAA receptors in the brain to create improved therapies for sleep, anxiety, stress, epilepsy, and other neuropsychiatric conditions.
Neurosteroids: Endogenous allosteric modulators of GABAA receptors
- BiologyPsychoneuroendocrinology
- 2009
Structural basis for GABAA receptor potentiation by neurosteroids
- BiologyNature Structural & Molecular Biology
- 2017
Crystal structures of a chimeric GABAAR construct in apo and pregnanolone-bound states are reported, illustrating how peripheral lipid ligands can regulate the desensitization gate of GABAARs, a process of broad relevance to pentameric ligand-gated ion channels.
GABA-A Receptors Mediate Tonic Inhibition and Neurosteroid Sensitivity in the Brain.
- BiologyVitamins and hormones
- 2018
References
SHOWING 1-10 OF 31 REFERENCES
Neurosteroid Access to the GABAA Receptor
- Biology, ChemistryThe Journal of Neuroscience
- 2005
Neuroactive steroids do not require direct aqueous access to the receptor, and membrane accumulation is required for receptor modulation, according to current views of receptor modulation.
The Contraceptive Agent Provera Enhances GABAA Receptor-Mediated Inhibitory Neurotransmission in the Rat Hippocampus: Evidence for Endogenous Neurosteroids?
- BiologyThe Journal of Neuroscience
- 2003
It is shown that low concentrations of ganaxolone, but not of 5α3α, enhance inhibitory transmission in dentate gyrus, whereas both steroids are similarly effective in CA1 neurons, suggesting a novel action by the contraceptive agent on inhibitory centers in the CNS.
Neurosteroids: endogenous regulators of the GABAA receptor
- BiologyNature Reviews Neuroscience
- 2005
GABAA (γ-aminobutyric acid type A) receptors mediate most of the 'fast' synaptic inhibition in the mammalian brain and are targeted by many clinically important drugs. Certain naturally occurring…
Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications.
- BiologyPharmacology & therapeutics
- 2003
Ethanol regulation of gamma-aminobutyric acid A receptors: genomic and nongenomic mechanisms.
- BiologyPharmacology & therapeutics
- 2004
An overview of recent data pertaining to mechanisms that could be responsible for altered properties and expression of GABA(A) receptors following chronic ethanol administration is provided.
Sites of positive allosteric modulation by neurosteroids on ionotropic γ‐aminobutyric acid receptor subunits
- BiologyFEBS letters
- 2004
Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by δ subunit-containing GABAA receptors
- Biology, PsychologyProceedings of the National Academy of Sciences of the United States of America
- 2003
It is reported that, at concentrations known to occur in vivo, neuroactive steroids specifically enhance a tonic inhibitory conductance in central neurons that is mediated by extrasynaptic δ subunit-containing GABAARs.
Neurosteroid Biosynthesis in the Human Brain and Its Clinical Implications
- Biology, MedicineAnnals of the New York Academy of Sciences
- 2003
Improved knowledge of the biochemical pathways of neurosteroidogenesis and their actions on the brain may enable new perspectives in the understanding of the physiology of the human brain as well as in the pharmacological treatment of its disturbances.
The role of pregnane neurosteroids in ethanol withdrawal: behavioral genetic approaches.
- Medicine, BiologyPharmacology & therapeutics
- 2004